A novel minimally invasive method, FFRangio, using artificial intelligence, assesses coronary artery plaques without the need for wire-based procedures, demonstrating similar patient outcomes compared to traditional techniques. The findings were presented at the ACC.26 Annual Scientific Session and published in the New England Journal of Medicine. Led by Dr. Ajay J. Kirtane, the ALL-RISE trial involved 1,930 patients across multiple countries, showing that 6.9% of FFRangio patients experienced adverse events versus 7.1% in the wire-based group. This approach, which requires just a standard angiogram, could enhance the adoption of coronary physiologic testing as per current guidelines. While FFRangio exhibited faster results and reduced procedural complexity, limitations included a non-blinded study design and exclusion of patients with prior bypass surgery. Future analyses will explore cost-effectiveness compared to conventional assessments. The research highlights a significant advance in coronary artery disease diagnosis and treatment strategies.
